Spectrum of cross‐photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non‐benzophenone‐containing molecules

Durbize, E; Vigan, M.; Puzenat, E; Girardin, P.; Adessi, B.; Ph, Desprez; Humbert, Ph.; Laurent, R.; Aubin, F.

doi:10.1034/j.1600-0536.2003.00066.x

Cited by 60 publications

(50 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients with a history of PACD from ketoprofen had positive patch test and/or photopatch test reactions to 1 or more of the different allergens that are usually positive in such patients, in particular, fragrance components (Table 4). 10 …”

Section: Resultsmentioning

confidence: 99%

Octocrylene, an Emerging Photoallergen

Avenel-Audran

Dutartre²,

Goossens³

et al. 2010

Arch Dermatol

112

102

View full text Add to dashboard Cite

Background: Octocrylene is a new emerging photoallergen. We report and discuss 50 cases of photoallergic contact dermatitis from octocrylene use and/or positive photopatch test reactions to this UV filter and draw attention to the unexpected association in adults with a history of photoallergic contact dermatitis from ketoprofen.Observations: Patients were divided in 3 groups: group A comprised 11 children; group B, 28 adults with a history of photoallergy from sunscreen products; and group C, 14 adults systematically tested with octocrylene because of a history of photoallergy from ketoprofen. All patients but 3 in group C had positive test reactions to octocrylene. Ten of 11 children in group A and 9 of 28 adults in group B had positive patch test reactions to octocrylene. One child in group A, the other 19 adults in group B, and 11 of 14 adults in group C had positive pho-

show abstract

Section: Resultsmentioning

confidence: 99%

Octocrylene, an Emerging Photoallergen

Avenel-Audran

Dutartre²,

Goossens³

et al. 2010

Arch Dermatol

112

102

View full text Add to dashboard Cite

show abstract

“…Les lésions régressent progressivement à l'arrêt du médicament et un traitement par dermocorticoïde permet d'améliorer l'éruption. Celle-ci peut persister plusieurs mois ou années avec une photo-rémanence à l'image de la photoallergie induite par le kétoprofène [86].…”

Section: Photoallergieunclassified

Toxidermies

Lebrun‐Vignes

Valeyrie‐Allanore

2015

La Revue de Médecine Interne

View full text Add to dashboard Cite

Cutaneous adverse drug reactions (CADR) represent a heterogeneous field including various clinical patterns without specific features suggesting drug causality. Exanthematous eruptions, urticaria and vasculitis are the most common forms of CADR. Fixed eruption is uncommon in western countries. Serious reactions (fatal outcome, sequelae) represent 2% of CADR: bullous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), DRESS (drug reaction with eosinophilia and systemic symptoms or drug-induced hypersensitivity syndrome) and acute generalized exanthematous pustulosis (AGEP). These forms must be quickly diagnosed to guide their management. The main risk factors are immunosuppression, autoimmunity and some HLA alleles in bullous reactions and DRESS. Most systemic drugs may induce cutaneous adverse reactions, especially antibiotics, anticonvulsivants, antineoplastic drugs, non-steroidal anti-inflammatory drugs, allopurinol and contrast media. Pathogenesis includes immediate or delayed immunologic mechanism, usually not related to dose, and pharmacologic/toxic mechanism, commonly dose-dependent or time-dependent. In case of immunologic mechanism, allergologic exploration is possible to clarify drug causality, with a variable sensitivity according to the drug and to the CADR type. It includes epicutaneous patch testing, prick test and intradermal test. However, no in vivo or in vitro test can confirm the drug causality. To determine the cause of the eruption, a logical approach based on clinical characteristics, chronologic factors and elimination of differential diagnosis is required, completed with a literature search. A reporting to pharmacovigilance network is essential in case of a serious CADR whatever the suspected drug and in any case if the involved drug is a newly marketed one or unusually related to cutaneous reactions.

show abstract

“…Many clinical cases have documented photosensitive contact dermatitis of ketoprofen gels (Durbize et al, 2003;Vigan et al, 2002;Durieu et al, 2001;Veyrac et al, 2002). For phototoxic skin reactions of ketoprofen, many studies have been carried out in vitro.…”

Section: Introductionmentioning

confidence: 99%

Phototoxicity Study of a Ketoprofen Poultice in Guinea Pigs

et al. 2005

View full text Add to dashboard Cite

-Ketoprofen has been reported to have such side effects as photosensitive dermatitis in humans (The Ministry of Health, Labour and Welfare, 2001). In the present study, as part of a safety evaluation of Miltax ® , an application drug containing ketoprofen, phototoxicity of Miltax ® was examined in guinea pigs.In the present skin phototoxicity study, Miltax ® was applied for 12 hr. Ultraviolet (UV) rays were irradiated to examine whether or not Miltax ® elicited skin reaction. Two kinds of UV-A plus UV-B dual irradiation and UV-A single irradiation were used for the elicitation. With UV-A plus UV-B dual irradiation on the Miltax ® application site, no skin reaction was observed at UV irradiation side in any animals, in contrast to the case of the positive control article, . Similar results were obtained with UV-A single irradiation.From these results, Miltax ® that contained ketoprofen did not show any skin phototoxicity in the guinea pig.

show abstract

Spectrum of cross‐photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non‐benzophenone‐containing molecules

Cited by 60 publications

References 17 publications

Octocrylene, an Emerging Photoallergen

Octocrylene, an Emerging Photoallergen

Toxidermies

Phototoxicity Study of a Ketoprofen Poultice in Guinea Pigs

Contact Info

Product

Resources

About